secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001104659-24-053506
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium enters authorized generic agreement with Hikma for Nucynta IR and ER
------------------------------------------------------------------------------

- Hikma gains exclusive US marketing rights for authorized generics of Nucynta IR and ER; launch 30 days before LOE.
- Collegium receives profit share starting in mid-80% range, declining based on third-party generic equivalents entering.
- Collegium will supply Nucynta AG products at fully burdened manufacturing cost; Hikma purchases exclusively from Collegium.
- Hikma cannot market its own generic equivalents of Nucynta while marketing the authorized generics.
- Initial term 5 years with auto-renewal; termination for material breach or bankruptcy; Hikma may terminate with 1-year notice after first anniversary of launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924053506/0001104659-24-053506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924053506/tm2412857d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-053506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer